The wellness firm sees super-strong weeds on the coronary heart of a super-powerful antiaging pores and skin spray
Article content continued
The new delivery systems are promising, explains Wellfully. For example, ultrasound diffusion is said to enable the skin to absorb droplets that are 50 times smaller than a conventional spray, while a magnetic mist acts on these droplets to allow significantly better penetration and absorption.
“The potential for this stronger blend of cannabinoids and their unique activation pathways will be key to treating anti-inflammatory conditions that are associated with certain diseases,” the company said.
Photo by Wellfully, PR Newswire
“We plan to address the needs of both the health category to treat inflammatory diseases, arthritis, rosacea and muscle regeneration damage, and beauty against anti-aging, acne, blemishes and beyond,” said Paul Peros, CEO of Wellfully.
It is expected that clinical trials analyzing the bioefficacy of seven major cannabis strains can begin in about 12 months. The products will be launched in the UK as early as 2022 via the Wellfully’s Reduit brand in the UK.
Researchers at the University of Colorado in a study published in 2017 concluded that “Medicines containing cannabinoids may be effective against eczema, psoriasis, atopy and contact dermatitis”.
Photo by Cunaplus_M.Faba / iStock / Getty Images Plus
Dr. Robert Dellavalle, Associate Professor of Dermatology at the University of Colorado Medical School, said, “Perhaps the most promising role for cannabinoids is in treating itching.”
A study published earlier this year examining cannabinoids and skin inflammation found that cannabinoids are increasingly being used to treat skin conditions with an inflammatory component. The paper dealt with in vivo and in vitro studies with phyto-, endo- or synthetic cannabinoids.
“Despite the promising early results, more controlled human studies are needed to determine the definitive role of these products in the pathophysiology of skin inflammation and their usefulness in the clinical setting,” the researchers wrote.